Lifetime risk of heart failure and trends in incidence rates among individuals with type 2 diabetes between 1995 and 2018
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Lifetime risk of heart failure and trends in incidence rates among individuals with type 2 diabetes between 1995 and 2018. / Schwartz, Brian; Pierce, Colin; Vasan, Ramachandran S.; Schou, Morten; Ibrahim, Michel; Monahan, Kevin; Lyass, Asya; Malmborg, Morten; Gislason, Gunnar H.; Køber, Lars; Torp-Pedersen, Christian; Andersson, Charlotte.
I: Journal of the American Heart Association, Bind 10, Nr. 21, e021230, 2021.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Lifetime risk of heart failure and trends in incidence rates among individuals with type 2 diabetes between 1995 and 2018
AU - Schwartz, Brian
AU - Pierce, Colin
AU - Vasan, Ramachandran S.
AU - Schou, Morten
AU - Ibrahim, Michel
AU - Monahan, Kevin
AU - Lyass, Asya
AU - Malmborg, Morten
AU - Gislason, Gunnar H.
AU - Køber, Lars
AU - Torp-Pedersen, Christian
AU - Andersson, Charlotte
N1 - Publisher Copyright: © 2021 The Authors.
PY - 2021
Y1 - 2021
N2 - BACKGROUND: There are limited data on the lifetime risk of heart failure (HF) in people with type 2 diabetes and how incidence has changed over time. We estimated the cumulative incidence and incidence rates of HF among Danish adults with type 2 diabetes between 1995 and 2018 using nationwide data. METHODS AND RESULTS: In total, 398 422 patients (49% women) with type 2 diabetes were identified. During follow-up, 36 400 (9%) were diagnosed with HF and 121 459 (30%) were censored due to death. Using the Aalen-Johansen estimators, accounting for the risk of death, the estimated residual lifetime risk of HF at age 50 years was calculated as 24% (95% CI 22%– 27%) in women and 27% (25%–28%) in men. During the observational period, the proportion of patients treated with statins, angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, and metformin increased from <30% to >60%. Similarly, the annual incidence rates of HF decreased significantly, with declines being greater in older versus younger individuals (5% versus 2% in age >50 versus ≤50 years, respectively; P<0.0001) and in women versus men (5% versus 4%, P=0.02), but similar in patients with and without IHD (4% versus 4%, P=0.53). CONCLUSIONS: The current lifetime risk of HF in type 2 diabetes approximates 1 in 4 for men and women. Paralleled by an increase in use of evidence-based pharmacotherapy over the past decades, the risk of developing HF has declined across several subgroups and regardless of underlying IHD, suggesting that optimal diabetes treatment can mitigate HF risk.
AB - BACKGROUND: There are limited data on the lifetime risk of heart failure (HF) in people with type 2 diabetes and how incidence has changed over time. We estimated the cumulative incidence and incidence rates of HF among Danish adults with type 2 diabetes between 1995 and 2018 using nationwide data. METHODS AND RESULTS: In total, 398 422 patients (49% women) with type 2 diabetes were identified. During follow-up, 36 400 (9%) were diagnosed with HF and 121 459 (30%) were censored due to death. Using the Aalen-Johansen estimators, accounting for the risk of death, the estimated residual lifetime risk of HF at age 50 years was calculated as 24% (95% CI 22%– 27%) in women and 27% (25%–28%) in men. During the observational period, the proportion of patients treated with statins, angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, and metformin increased from <30% to >60%. Similarly, the annual incidence rates of HF decreased significantly, with declines being greater in older versus younger individuals (5% versus 2% in age >50 versus ≤50 years, respectively; P<0.0001) and in women versus men (5% versus 4%, P=0.02), but similar in patients with and without IHD (4% versus 4%, P=0.53). CONCLUSIONS: The current lifetime risk of HF in type 2 diabetes approximates 1 in 4 for men and women. Paralleled by an increase in use of evidence-based pharmacotherapy over the past decades, the risk of developing HF has declined across several subgroups and regardless of underlying IHD, suggesting that optimal diabetes treatment can mitigate HF risk.
KW - Cumulative risk
KW - Heart failure
KW - Incidence rate
KW - Temporal trends
KW - Type 2 diabetes
U2 - 10.1161/JAHA.121.021230
DO - 10.1161/JAHA.121.021230
M3 - Journal article
C2 - 34713706
AN - SCOPUS:85120830742
VL - 10
JO - Journal of the American Heart Association
JF - Journal of the American Heart Association
SN - 2047-9980
IS - 21
M1 - e021230
ER -
ID: 301820680